Tue.May 21, 2024

article thumbnail

AstraZeneca, on fast track of growth, sets revenue target at $80B by 2030

Fierce Pharma

A decade ago, with AstraZeneca in decline and some investors urging the drugmaker to sell out to Pfizer, new CEO Pascal Soriot presented an audacious plan to hike revenue to $45 billion by 2023. | After AstraZeneca achieved Pascal Soriot's ambitious $45-billion-by-2023 revenue goal, the CEO is thinking big again. On Tuesday morning, AZ unveiled its new plan to swell its revenue to $80 billion by 2030.

306
306
article thumbnail

Introducing the Clarivate Academic AI Platform

Clarivate

We have released the first version of the Clarivate Academic AI Platform, serving our suite of AI-powered Research Assistants. Discover how it is going to help address the needs of students, researchers and librarians for trusted AI. At Clarivate TM , we understand the transformative power of artificial intelligence (AI) in the academic realm and the imperative to introduce AI thoughtfully and responsibly into research, teaching and learning environments.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Lilly pads case for mirikizumab in its next potential indication in Crohn's disease

Fierce Pharma

Following last year’s hard-won ulcerative colitis nod for Eli Lilly’s Omvoh, also known as mirikizumab, the Indianapolis-based drugmaker is padding the case for its antibody’s next potential immuno | Following last year’s hard-won ulcerative colitis nod for Eli Lilly’s Omvoh, also known as mirikizumab, the Indianapolis-based drugmaker is padding the case for its antibody’s next potential immunology approval.

262
262
article thumbnail

Why Healthcare Data Is Vital for Employers

MedCity News

Employers need healthcare data in order to make decisions, but the data isn’t always easy to get, experts said on a panel at MedCity INVEST. The post Why Healthcare Data Is Vital for Employers appeared first on MedCity News.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Incyte plots Delaware expansion as it looks to re-wed commercial, medical teams in its home state

Fierce Pharma

As Incyte Corporation continues its growth momentum thanks to JAK inhibitors Jakafi and Opzelura, the company is bringing its U.S. | Incyte revealed plans to purchase buildings at 1100 North King Street and 1100 North French street in downtown Wilmington, Delaware, where the company got its start back in 2002.

Medical 261
article thumbnail

5 Things to Know About How NIH’s SEED Can Help Life Science Startups Grow

MedCity News

The NIH’s SEED office formed to help startups leverage government’s funding programs. Chris Sasiela, director of the SEED office, discussed these programs during the MedCity News INVEST Conference in Chicago. The post 5 Things to Know About How NIH’s SEED Can Help Life Science Startups Grow appeared first on MedCity News.

Biopharma 115

More Trending

article thumbnail

FOCUS ON: Connected TV

PM360

PM360’s Focus On section examines a specific area of the life sciences industry. In this issue, we take a closer look at the evolution of the Smart TV and the increase of streaming services and how they can benefit the pharma industry. From connecting with patients by interactive ads to dabbling into cross-platform integration, here is what our specialists had to say.

Media 105
article thumbnail

FDA competition seeks digital endpoints for Parkinson’s

pharmaphorum

FDA is asking artificial intelligence teams to develop a digital endpoint tool to study freezing of gait, a symptom of Parkinson’s that can have a serious impact on patients.

article thumbnail

4 Things Digital Health Investors Need To Get Off Their Chest

MedCity News

During a panel at MedCity News’ INVEST conference, venture capitalists shared some of their takes on today’s healthcare funding landscape — including their thoughts on AI and the industry’s slower investment pace. The post 4 Things Digital Health Investors Need To Get Off Their Chest appeared first on MedCity News.

article thumbnail

AstraZeneca sets lofty target of $80bn in revenues by 2030

pharmaphorum

AstraZeneca CEO Pascal Soriot says group revenues can reach $80bn by 2030, fuelled by a pipeline that features 'many' potential $5bn-plus candidates.

107
107
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

The Power of Grip: A Journey from Adversity to Success in the Consumer Goods Industry

Scott Burrows

In the world of motivational speaking, stories of triumph over adversity are not uncommon. But for me, the narrative goes beyond inspiration—it’s about embodying the very principles of vision, mindset, and grit that have shaped my journey. At the age of 19, a car accident left me with a broken neck and a daunting diagnosis of quadriplegia. But from the confines of a wheelchair, I refused to let my circumstances define me.

article thumbnail

EU rules PTC’s Duchenne drug can stay on the market

pharmaphorum

Going against the advice of the CHMP, the EU has said that PTC Therapeutics’ Translarna therapy for Duchenne muscular dystrophy should stay on the market

article thumbnail

Importance of Patient Capital in Life Sciences

MedCity News

The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development. The post Importance of Patient Capital in Life Sciences appeared first on MedCity News.

article thumbnail

Novel biologic could offer ulcerative colitis symptomatic remission

European Pharmaceutical Review

Initial data from a Phase III maintenance study of TREMFYA ® (guselkumab) has demonstrated promising remission rates obtained from a dual-acting monoclonal antibody given to ulcerative colitis (UC) patients. This data from Johnson & Johnson’s Phase III QUASAR study is being presented at Digestive Disease Week 2024 (Abstract #759). Achievement of clinical remission Fifty percent of patients with moderate to severe active ulcerative colitis given subcutaneous TREMFYA (guselkumab) 200mg every f

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

3 up-and-coming US biotech hotspots

PharmaVoice

These three U.S. cities are putting themselves on the biotech map as unsung hubs of the industry.

116
116
article thumbnail

Effects of the Federal Trade Commission's Repeal of Non-Compete Agreements on the Pharma Industry

Pharmaceutical Commerce

In an interview with Pharma Commerce Associate Editor Don Tracy, Ron Lanton, Partner, Lanton Law offers his thoughts on the recent Federal Trade Commission (FTC) repeal of non-compete agreements, and how it could effect the pharma industry.

Pharma 81
article thumbnail

Roche’s PI3K inhibitor secures breakthrough status in breast cancer

Pharmaceutical Technology

Roche announced an FDA breakthrough therapy designation for its inavolisib/Ibrance combination therapy.

FDA 98
article thumbnail

Internal budgets ‘holding back pharma’s digital evolution’

pharmaphorum

Digital investment in the pharma sector is continuing at a steady pace but could fall behind what is needed to deliver true transformation of their businesses.

Pharma 77
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

NIHR awards HealthTech Research Centre Network £5m to advance health innovations

PharmaTimes

The network will support the development, evaluation and adoption of innovative health and care technology

article thumbnail

Pharma Pulse 5/21/24: Hims & Hers Announces Access to GLP-1 Injections, The Impact of the Presidential Election on Pharma & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 99
article thumbnail

NHS addresses shortage of ethnic organ and blood donors with £600,000 funding

PharmaTimes

The funding aims to reduce health inequalities in these groups and save more lives

85
article thumbnail

IndustryBRIEFS

PM360

EVERSANA and MyHealthTeam collaborate to help patients connect more quickly on social media regarding diagnosis and treatment. EVERSANA and MyHealthTeam Collaborate to Launch Direct-to-Patient Solution EVERSANA and MyHealthTeam announced that they have joined forces to help life sciences companies use the power of Artificial Intelligence (AI) and accelerate the time to diagnosis and treatment for millions of patients all over the world.

Media 52
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

US Pharma and Biotech Summit 2024: Artificial Intelligence and Machine Learning Through the Eyes of the FDA Part II

PharmExec

In an interview with Pharm Exec Associate Editor Don Tracy, Tala Fakhouri, at Financial Times’ US Pharma and Biotech Summit, Tala Fakhouri, Associate Director for Policy Analysis, FDA, discusses whether the FDA plans on restricting the use of AI and what the future could look like when it comes to machine learning.

FDA 52
article thumbnail

Changing the Conversation About Women in Pharma

PM360

Gender imbalance was so ingrained in me as I grew up that, even as a woman, I have at times in my career been gender- blind. I was lucky enough to enter academia with a number of women colleagues. It was only later in my career that I started noticing the gender gap in the pharma industry. Minding the Gap In 2012, I was invited to a life science and pharma event in London as part of the Olympics.

Pharma 52
article thumbnail

Beyond overall survival: Time to agree on the value of alternative oncology endpoints?

Clarivate

With the goal of cancer treatment generally to extend a patient’s life for a meaningful length of time, overall survival (OS) is widely considered the ‘gold standard’ endpoint in oncology clinical trials [1] [2]. However, alternative oncology-relevant endpoints beyond OS offer great potential for supporting faster and more efficient access to therapies.

article thumbnail

Driving Adherence with AI—Possibilities and Guardrails

PM360

From 19th century fiction like Pinocchio to modern science fiction like Star Trek, Artificial Intelligence (AI) has intrigued us with existential dilemmas and life-changing potential. It is unsurprising then that AI’s arrival has impacted Life Sciences so profoundly. AI has driven major advances across the Life Sciences value chain from molecule discovery to clinical trials to manufacturing.

Medical 52
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Transforming Adversity into Inspiration: A Journey of Vision, Mindset, and Grit

Scott Burrows

In the world of keynote motivational speakers, there are those who inspire with words, and then there are those who inspire with their very existence. My journey, marked by triumph over adversity, serves as a testament to the power of the human spirit and the principles that guide us through life’s toughest challenges: vision, mindset, and grit.

Safety 52
article thumbnail

Modular Content in Pharmaceutical Marketing

PM360

In the ever-evolving landscape of pharmaceutical marketing, staying ahead necessitates innovation and adaptability. Traditional marketing approaches, while effective in the past, often struggle to engage modern audiences inundated with information from various channels. Enter modular content—a dynamic strategy that holds immense potential for pharmaceutical marketers seeking to connect meaningfully with their target audience.

article thumbnail

From Setback to Success: Inspiring Financial Advisors to Thrive in a Competitive Landscape

Scott Burrows

As an Inspirational Business and Sales Keynote speaker entrenched in the insurance and financial industry, I have a unique story to tell—one of resilience, determination, and ultimate triumph. My life-changing journey serves as the foundation for my presentations, where I strive to inspire audiences to believe that anything is possible, both personally and professionally.

article thumbnail

Engaging Patients in More Moments Along Their Care Journey

PM360

Navigating the complex healthcare system can be a stressful experience for patients, from obtaining a diagnosis to finding the right specialty care or treatment. To help alleviate some of the challenges patients face, it’s crucial to meet them with personalized resources that fit their needs at different stages throughout their journey. And thanks to recent innovations, that’s possible at the point of care and beyond.

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.